Omega Diagnostics: Funding, Investors & Team (Sep 2026)
Omega Diagnostics Group PLC, through its subsidiaries, engages in the manufacture, development, and distribution of medical diagnostic products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Disease. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in vitro allergy and autoimmune tests that are used by doctors to diagnose patients with allergies and autoimmune diseases. This segment’s principal products include Allergozyme, Allergodip, and Genesis Elisa. The Food Intolerance segment engages in the research, development, and production of kits that are used in the detection of immune reactions to food. It also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies consumer food detective test. This segment’s principal products include Genarrayt microarray, Food Detective, and Foodprint service. The Infectious Disease segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases, such as syphilis, tuberculosis, dengue fever, Chagas disease, and malaria. Its principal products comprise Immutrep Syphilis, Micropath Bacterial tests, and Dengue Elisa. The company offers its diagnostic kits and systems to hospitals, blood banks, clinics, and laboratories through distributors in approximately 100 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.
Omega Diagnostics has raised $6.8M across 1 funding round on record, the most recent a Post-IPO Equity of $6.8M announced in Feb 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Omega Diagnostics Company Profile and Key Stats
Latest funding round on record: Feb 2022.
Omega Diagnostics Funding Rounds
Omega Diagnostics Founders and Leadership Team
No contact details are on record for this team yet.
Omega Diagnostics Funding Compared to Other Biotechnology Startups
Omega Diagnostics' latest round of $6.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Omega Diagnostics in Biotechnology and Alva
Companies Similar to Omega Diagnostics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Omega Diagnostics Funding FAQs
What does Omega Diagnostics do?
Omega Diagnostics Group PLC, through its subsidiaries, engages in the manufacture, development, and distribution of medical diagnostic products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Disease. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in vitro allergy and autoimmune tests that are used by doctors to diagnose patients with allergies and autoimmune diseases. This segment’s principal products include Allergozyme, Allergodip, and Genesis Elisa. The Food Intolerance segment engages in the research, development, and production of kits that are used in the detection of immune reactions to food. It also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies consumer food detective test. This segment’s principal products include Genarrayt microarray, Food Detective, and Foodprint service. The Infectious Disease segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases, such as syphilis, tuberculosis, dengue fever, Chagas disease, and malaria. Its principal products comprise Immutrep Syphilis, Micropath Bacterial tests, and Dengue Elisa. The company offers its diagnostic kits and systems to hospitals, blood banks, clinics, and laboratories through distributors in approximately 100 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.
How much funding has Omega Diagnostics raised?
Omega Diagnostics has raised $6.8M across 1 round on record. The most recent is a Post-IPO Equity of $6.8M announced in Feb 2022.
When did Omega Diagnostics last raise funding?
Omega Diagnostics' most recent funding round on record is a Post-IPO Equity of $6.8M, announced in Feb 2022.
Who is the CEO of Omega Diagnostics?
Jag Grewal is listed as CEO at Omega Diagnostics.
Where is Omega Diagnostics headquartered?
Omega Diagnostics is based in Alva, Clackmannanshire, United Kingdom.
How many employees does Omega Diagnostics have?
Omega Diagnostics is in the 101-250 employee band.
How does Omega Diagnostics' funding compare to other Biotechnology startups?
Omega Diagnostics' latest round of $6.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Omega Diagnostics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Omega Diagnostics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.